Developer docs
API playgroundTry for free, no card

Search company profiles

Novartis Malaysia

Full company profile

uuid004zn3m

Namestring
Novartis Malaysia
Legal namestring
Novartis Malaysia
Websiteurl
novartis.com.my
Company typeenum
Private
Founded yearstring
-
Descriptiontext

Novartis Malaysia is the Malaysian country subsidiary of Swiss-headquartered global pharmaceutical company Novartis AG (NYSE: NVS). Operating from Kuala Lumpur, the entity manages pharmaceutical sales, marketing, and healthcare professional engagement activities across Malaysia, distributing a portfolio of prescription medicines spanning oncology, immunology, neuroscience, cardiovascular, and respiratory therapeutic areas. The subsidiary operates within Malaysia's regulated pharmaceutical distribution framework, reaching patients through hospital and retail pharmacy channels and engaging physicians directly via enterprise field sales teams.

The subsidiary's primary digital offering is Novartis MedHub Malaysia, a responsive online medical information hub providing physicians and specialists with educational content, pipeline data, clinical trial information, and adverse event reporting capabilities. Beyond product commercialization, Novartis Malaysia runs disease awareness campaigns — including initiatives in breast cancer recurrence and prostate health — and has launched the MyNuCLEaR initiative to develop Malaysia's nuclear medicine ecosystem and improve patient access to radiopharmaceutical therapies.

Commercially, Novartis Malaysia generates revenue through prescription pharmaceutical product sales distributed via hospitals, pharmacies, and direct healthcare provider engagement. The entity targets three core customer segments: patients (primary), healthcare professionals (primary), and caregivers (secondary). With 109 employees and no separately disclosed revenue, the subsidiary operates as a wholly-owned regional unit within Novartis AG's Asia Pacific structure, with strategic direction and product pipeline flowing from the Swiss parent company.

Short descriptiontext

Novartis Malaysia is the Kuala Lumpur-based country subsidiary of global pharmaceutical company Novartis AG, commercializing prescription medicines across oncology, immunology, neuroscience, cardiovascular, and respiratory therapeutic areas through hospital, pharmacy, and healthcare professional channels in Malaysia.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersKuala Lumpur, Malaysia
HQ citystring
Kuala Lumpur
HQ countrystring
Malaysia
HQ regionstring
Asia
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
prescription pharmaceuticals, oncology medicines, cardiovascular therapies, neuroscience treatments, medical information services
Industry2 codes
1Primary Care & General Medicine Pharmaceuticals
CodeHLAIAAAAPrimaryYes
2Neurology & Psychiatry (CNS) Pharmaceuticals
CodeHLAIAAAFPrimaryNo
NAICS code1 code
  • Pharmaceutical Preparation Manufacturing325412
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Prescription Pharmaceuticals
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Product Sales
TypeOne Time License
Description

Novartis generates revenue through the sale of prescription medicines across multiple therapeutic areas including oncology, immunology, neuroscience, cardiovascular, and respiratory conditions. Products are distributed through hospitals, pharmacies, and directly to healthcare providers.

novartis.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Novartis Malaysia commercializes and distributes a portfolio of innovative prescription medicines across multiple therapeutic areas including oncology, immunology, neuroscience, cardiovascular, and respiratory conditions. Products are sold to hospitals, pharmacies, and healthcare providers across Malaysia. The subsidiary also operates Novartis MedHub Malaysia, a digital medical information hub where physicians access educational content, clinical resources, and adverse event reporting tools.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • 769 million lives touched by Novartis products globally
Product overview1 text field

Novartis Malaysia operates as the Malaysian subsidiary of global pharmaceutical company Novartis AG. The company offers a portfolio of pharmaceutical products across multiple therapeutic areas, supported by Novartis MedHub Malaysia as a dedicated online medical information hub for healthcare professionals. The product ecosystem includes clinical trial information (Novartis Clinical Trials), pipeline visibility (Novartis Pipeline), and access to the broader Novartis Product Portfolio. MedHub serves as the primary digital service offering connecting healthcare professionals with educational resources and medical information.

Product and service2 records
1Novartis MedHub Malaysia
CategoryDigital Medical Information Platform
Description

A responsive online medical information hub where physicians and healthcare professionals in Malaysia can access educational content, clinical resources, pipeline data, and adverse event reporting tools tailored to the Malaysian market.

2Novartis Pharmaceutical Product Portfolio (Malaysia)
CategoryPrescription Pharmaceuticals
Description

A portfolio of innovative prescription medicines commercialized and distributed in Malaysia across multiple therapeutic areas including oncology, immunology, neuroscience, cardiovascular, and respiratory conditions. Products are distributed through hospitals, pharmacies, and directly to healthcare providers.

Scale indicator1 record

Each record includes

Type, Value, Description, Source

Recent move4 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
1Abbott Malaysia
TypeBroad incumbent
Description

Malaysian operations of Abbott Laboratories covering pharmaceuticals, diagnostics, nutrition, and medical devices; broader healthcare incumbent with overlapping pharmaceutical portfolio but a wider product range.

2Johnson & Johnson Malaysia
TypeDirect peer
Description

Malaysian affiliate of Johnson & Johnson selling pharmaceuticals (Janssen), medical devices, and consumer health; comparable diversified healthcare multinational with overlapping oncology and immunology portfolios.

3Bayer Malaysia
TypeDirect peer
Description

Malaysian subsidiary of Bayer AG marketing pharmaceuticals (especially cardiovascular and women's health), consumer health, and crop science; comparable branded pharma affiliate with overlapping cardiovascular portfolio.

4Pfizer Malaysia
TypeDirect peer
Description

Subsidiary of Pfizer Inc. selling branded prescription medicines in Malaysia across oncology, vaccines, internal medicine, and inflammation—directly comparable multinational pharma affiliate with similar sales/marketing footprint.

5Boehringer Ingelheim Malaysia
TypeDirect peer
Description

Malaysian affiliate of Boehringer Ingelheim selling prescription medicines in respiratory, cardiovascular, and specialty therapeutics; directly comparable multinational pharma subsidiary with similar enterprise sales approach.

6MSD (Merck) Malaysia
TypeDirect peer
Description

Malaysian subsidiary of Merck & Co. (known as MSD outside US) selling pharmaceuticals across oncology, vaccines, and specialty areas; comparable multinational pharma distribution model targeting similar hospital and pharmacy channels.

7GSK Malaysia (GlaxoSmithKline)
TypeDirect peer
Description

Subsidiary of GSK plc marketing vaccines, specialty medicines, and general pharmaceuticals in Malaysia; directly comparable multinational pharma affiliate targeting physicians and pharmacists.

8Roche Malaysia
TypeDirect peer
Description

Subsidiary of F. Hoffmann-La Roche selling pharmaceuticals and diagnostics in Malaysia with strong oncology and neuroscience portfolio overlap; directly competes in the same hospital channel and specialty therapeutic areas.

9AstraZeneca Malaysia
TypeDirect peer
Description

Malaysian affiliate of AstraZeneca PLC selling branded prescription drugs in oncology, cardiovascular, renal, and respiratory—directly overlapping with Novartis's therapeutic categories and HCP-targeted sales model.

10Sanofi Malaysia
TypeDirect peer
Description

Malaysian affiliate of Sanofi selling specialty care, vaccines, and general medicines; comparable branded pharma subsidiary with overlapping therapeutic areas and enterprise field sales approach.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Novartis Malaysia

Prescription Pharmaceuticalsnovartis.com.my

Novartis Malaysia is the Kuala Lumpur-based country subsidiary of global pharmaceutical company Novartis AG, commercializing prescription medicines across oncology, immunology, neuroscience, cardiovascular, and respiratory therapeutic areas through hospital, pharmacy, and healthcare professional channels in Malaysia.

What Novartis Malaysia does

Novartis Malaysia is the Malaysian country subsidiary of Swiss-headquartered global pharmaceutical company Novartis AG (NYSE: NVS). Operating from Kuala Lumpur, the entity manages pharmaceutical sales, marketing, and healthcare professional engagement activities across Malaysia, distributing a portfolio of prescription medicines spanning oncology, immunology, neuroscience, cardiovascular, and respiratory therapeutic areas. The subsidiary operates within Malaysia's regulated pharmaceutical distribution framework, reaching patients through hospital and retail pharmacy channels and engaging physicians directly via enterprise field sales teams.

The subsidiary's primary digital offering is Novartis MedHub Malaysia, a responsive online medical information hub providing physicians and specialists with educational content, pipeline data, clinical trial information, and adverse event reporting capabilities. Beyond product commercialization, Novartis Malaysia runs disease awareness campaigns — including initiatives in breast cancer recurrence and prostate health — and has launched the MyNuCLEaR initiative to develop Malaysia's nuclear medicine ecosystem and improve patient access to radiopharmaceutical therapies.

Commercially, Novartis Malaysia generates revenue through prescription pharmaceutical product sales distributed via hospitals, pharmacies, and direct healthcare provider engagement. The entity targets three core customer segments: patients (primary), healthcare professionals (primary), and caregivers (secondary). With 109 employees and no separately disclosed revenue, the subsidiary operates as a wholly-owned regional unit within Novartis AG's Asia Pacific structure, with strategic direction and product pipeline flowing from the Swiss parent company.

Novartis Malaysia firmographics

Firmographics
Name
Novartis Malaysia
Legal name
Novartis Malaysia
Website
https://novartis.com.my
Company type
Private
Operating status
Operating
Headcount range
101–250 employees
Short description
Novartis Malaysia is the Kuala Lumpur-based country subsidiary of global pharmaceutical company Novartis AG, commercializing prescription medicines across oncology, immunology, neuroscience, cardiovascular, and respiratory therapeutic areas through hospital, pharmacy, and healthcare professional channels in Malaysia.
Ownership category
akta.pro rank

Novartis Malaysia industry classification

Industry
Product category
Prescription Pharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412)
SIC
Pharmaceutical Preparations (2834)
akta.pro primary industry
Primary Care & General Medicine Pharmaceuticals (HLAIAAAA)
akta.pro secondary industry
Neurology & Psychiatry (CNS) Pharmaceuticals (HLAIAAAF)

Keywords

  • Prescription pharmaceuticals
  • Oncology medicines
  • Cardiovascular therapies
  • Neuroscience treatments
  • Medical information services

Where Novartis Malaysia is headquartered

Location

Headquarters

HQ city
Kuala Lumpur
HQ country
Malaysia
HQ region
Asia

Offices1 record

Markets served

Novartis Malaysia business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations

Revenue model

  1. Pharmaceutical Product Sales: Novartis generates revenue through the sale of prescription medicines across multiple therapeutic areas including oncology, immunology, neuroscience, cardiovascular, and respiratory conditions. Products are distributed through hospitals, pharmacies, and directly to healthcare providers.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels3 records

Novartis Malaysia product offering

Product offering

Core offering

Novartis Malaysia commercializes and distributes a portfolio of innovative prescription medicines across multiple therapeutic areas including oncology, immunology, neuroscience, cardiovascular, and respiratory conditions. Products are sold to hospitals, pharmacies, and healthcare providers across Malaysia. The subsidiary also operates Novartis MedHub Malaysia, a digital medical information hub where physicians access educational content, clinical resources, and adverse event reporting tools.

Product overview

Novartis Malaysia operates as the Malaysian subsidiary of global pharmaceutical company Novartis AG. The company offers a portfolio of pharmaceutical products across multiple therapeutic areas, supported by Novartis MedHub Malaysia as a dedicated online medical information hub for healthcare professionals. The product ecosystem includes clinical trial information (Novartis Clinical Trials), pipeline visibility (Novartis Pipeline), and access to the broader Novartis Product Portfolio. MedHub serves as the primary digital service offering connecting healthcare professionals with educational resources and medical information.

Differentiator

Problem solved

Functional benefit

Products and services

  • Novartis MedHub Malaysia A responsive online medical information hub where physicians and healthcare professionals in Malaysia can access educational content, clinical resources, pipeline data, and adverse event reporting tools tailored to the Malaysian market.
  • Novartis Pharmaceutical Product Portfolio (Malaysia) A portfolio of innovative prescription medicines commercialized and distributed in Malaysia across multiple therapeutic areas including oncology, immunology, neuroscience, cardiovascular, and respiratory conditions. Products are distributed through hospitals, pharmacies, and directly to healthcare providers.

Quantifiable outcome

  • 769 million lives touched by Novartis products globally

Companies that use Novartis Malaysia

Customer profile

Segments3 records

Ideal customer profiles2 records

Novartis Malaysia technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Novartis Malaysia partnerships and signals

Strategic signal

Scale indicators1 record

Recent moves4 records

Expansion highlights4 records

Novartis Malaysia competitors and assessment

Company assessment

Broad incumbents

  • Abbott Malaysia: Malaysian operations of Abbott Laboratories covering pharmaceuticals, diagnostics, nutrition, and medical devices; broader healthcare incumbent with overlapping pharmaceutical portfolio but a wider product range.

Direct peers

  • Johnson & Johnson Malaysia: Malaysian affiliate of Johnson & Johnson selling pharmaceuticals (Janssen), medical devices, and consumer health; comparable diversified healthcare multinational with overlapping oncology and immunology portfolios.
  • Bayer Malaysia: Malaysian subsidiary of Bayer AG marketing pharmaceuticals (especially cardiovascular and women's health), consumer health, and crop science; comparable branded pharma affiliate with overlapping cardiovascular portfolio.
  • Pfizer Malaysia: Subsidiary of Pfizer Inc. selling branded prescription medicines in Malaysia across oncology, vaccines, internal medicine, and inflammation—directly comparable multinational pharma affiliate with similar sales/marketing footprint.
  • Boehringer Ingelheim Malaysia: Malaysian affiliate of Boehringer Ingelheim selling prescription medicines in respiratory, cardiovascular, and specialty therapeutics; directly comparable multinational pharma subsidiary with similar enterprise sales approach.
  • MSD (Merck) Malaysia: Malaysian subsidiary of Merck & Co. (known as MSD outside US) selling pharmaceuticals across oncology, vaccines, and specialty areas; comparable multinational pharma distribution model targeting similar hospital and pharmacy channels.
  • GSK Malaysia (GlaxoSmithKline): Subsidiary of GSK plc marketing vaccines, specialty medicines, and general pharmaceuticals in Malaysia; directly comparable multinational pharma affiliate targeting physicians and pharmacists.
  • Roche Malaysia: Subsidiary of F. Hoffmann-La Roche selling pharmaceuticals and diagnostics in Malaysia with strong oncology and neuroscience portfolio overlap; directly competes in the same hospital channel and specialty therapeutic areas.
  • AstraZeneca Malaysia: Malaysian affiliate of AstraZeneca PLC selling branded prescription drugs in oncology, cardiovascular, renal, and respiratory—directly overlapping with Novartis's therapeutic categories and HCP-targeted sales model.
  • Sanofi Malaysia: Malaysian affiliate of Sanofi selling specialty care, vaccines, and general medicines; comparable branded pharma subsidiary with overlapping therapeutic areas and enterprise field sales approach.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Novartis Malaysia social profiles

Digital presence

Novartis Malaysia financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Novartis Malaysia leadership team

Management profile

Number of profiles

Novartis Malaysia funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Novartis Malaysia M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Novartis Malaysia

What does Novartis Malaysia do?

Novartis Malaysia commercializes and distributes a portfolio of innovative prescription medicines across multiple therapeutic areas including oncology, immunology, neuroscience, cardiovascular, and respiratory conditions. Products are sold to hospitals, pharmacies, and healthcare providers across Malaysia. The subsidiary also operates Novartis MedHub Malaysia, a digital medical information hub where physicians access educational content, clinical resources, and adverse event reporting tools.

Is Novartis Malaysia a public or private company?

Novartis Malaysia is a private company. It is classified as corporate owned and is currently operating.

When was Novartis Malaysia founded?

Novartis Malaysia was founded in -1. It employs 101 to 250 people.

Where is Novartis Malaysia based?

Novartis Malaysia is headquartered in Kuala Lumpur, Malaysia, in the Asia region.

How does Novartis Malaysia make money?

One revenue line is on record: pharmaceutical Product Sales.

Who are Novartis Malaysia's main competitors?

Abbott Malaysia is listed as a broad incumbent. Direct peers are Johnson & Johnson Malaysia, Bayer Malaysia, Pfizer Malaysia, Boehringer Ingelheim Malaysia, MSD (Merck) Malaysia, GSK Malaysia (GlaxoSmithKline), Roche Malaysia, AstraZeneca Malaysia and Sanofi Malaysia.

Does Novartis Malaysia have an API?

No public API is recorded for Novartis Malaysia.

What industry is Novartis Malaysia in?

Novartis Malaysia's product category is Prescription Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAA, Primary Care & General Medicine Pharmaceuticals, with a secondary code of HLAIAAAF, Neurology & Psychiatry (CNS) Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales